THERAPIES FOR IMPROVING PULMONARY FUNCTION

摘要

The disclosure relates to IL-13 antagonists, in particular anti -human- IL- 13 antibodies and human - IL - 13 -binding fragments thereof, and their use for improvement, maintenance or reduction in the rate of decline of pulmonary function in a subject with impaired pulmonary function, which may be associated with asthma, COPD or IPF.